The private Huifu Pharmaceutical Factory was established in 1951, which was the predecessor of Tianjin Lisheng Pharmaceutical Co., Ltd.

In 1956, a public-private partnership was established mainly with Huifu Pharmaceutical and other factories.

In 1964, it moved to a new location and changed its name to: Tianjin Public-Private Partnership Lisheng Pharmaceutical Factory.

In 1966, it was incorporated into the ranks of state-owned enterprises and renamed: Tianjin Lisheng Pharmaceutical Factory.

In 1983, injection molding machines were introduced from the United States and Germany and a plastic bottle workshop was built.

In 1984, capsule filling machines and bubble eye packaging machines were introduced from Italy, and a 3,300 square meter production workshop close to GMP standards was built.

In 1985, the self-developed new product Gastric Gaping Tablets won the National Silver Award for Quality Products.

In 1988, Lisheng Pharmaceutical Factory became a reform pilot unit in Tianjin, and Mr. Sun Baowei became the legal representative of the company.

In 1988, indapamide was approved as a national Class II new drug.

In 1990, the male baby workshop was renovated to meet GMP standards and was certified by Japan's Tanabe Pharmaceutical Co., Ltd. Sanyu brand male baby was approved by the Japanese Ministry of Health and Welfare to enter the Japanese market.

In 1991, Sanyu brand "boy baby" was officially sold in the Japanese market.

In 1993, GMP transformation was implemented in the first workshop. On March 13 of the same year, "Tianjin Huisheng Taxi Company" was founded.

On August 17, 1993, "Tianjin Tanabe Pharmaceutical Co., Ltd." was established as a joint venture with Japan's Tanabe Pharmaceutical Co., Ltd.

On February 1, 1994, "Tianjin Takeda Pharmaceutical Co., Ltd." was established as a joint venture with Japan's Takeda Pharmaceutical Co., Ltd. On November 16 of the same year, "Tianjin Tanabe Pharmaceutical Co., Ltd." was opened.

On December 9, 1994, it obtained GMP certification from the Australian Ministry of Health.

On May 19, 1995, "Tianjin New Uchida Pharmaceutical Co., Ltd." was established as a joint venture with Japanese Uchida Wagyu Co., Ltd. and Shinwa Bussan Co., Ltd.

On December 14, 1995, "Tianjin IMA Machinery Co., Ltd." was established as a joint venture with the Italian IMA Company.

On February 5, 1996, "Tianjin Xinaida Pharmaceutical Co., Ltd." opened for business.

In August 1996, "Tianjin Takeda Pharmaceutical Co., Ltd." was opened.

In 1996, the new product itraconazole and olsalazine development projects were included in Tianjin’s key industry-university-research cooperation projects and the national “Ninth Five-Year Plan” key science and technology related projects.

On November 1, 1996, the "Tianjin Medicinal Glass Products Factory" was merged.

In February 1997, "Tianjin Lisheng Real Estate Co., Ltd." was founded.

In 1998, the GMP transformation of the fifth workshop (plastic bottle workshop) was completed, and the GMP transformation of the raw material warehouse and the first workshop was started.

On September 29, 1999, it passed the national GMP certification and obtained the "People's Republic of China and National Pharmaceutical GMP Certificate" issued by the State Food and Drug Administration.

In 2000, the national Class IV new drugs "Itraconazole" (raw material, capsules) and "Osalazine" (raw materials, capsules) obtained new drug certificates and production approval numbers.

In 2001, the company carried out joint-stock restructuring, and "Tianjin Lisheng Pharmaceutical Co., Ltd." established by sponsorship was officially established on August 8.

In 2002, we started to implement GMP transformation on the fifth workshop, the raw material workshop and the fine packaging process of the seventh workshop, the research institute was renovated and expanded, and the office was renovated.

In March 2002, the company passed the high-tech enterprise certification.

In August 2002, the company's Shoubishan brand indapamide tablets won the title of Tianjin Famous Brand Product.

In 2003, the GMP transformation of the second workshop, the dropping pill workshop, the fine packaging process of the raw material workshop and the seventh workshop was completed.

Passed Australian GMP re-inspection in April 2003.

In December 2003, the company fully passed GMP certification.

In 2003, the company won the National May Day Labor Award.

In 2004, it passed the re-inspection of the first and third workshops and the GMP certification of three raw materials: indapamide, donepezil hydrochloride and formoterol fumarate.

In March 2004, the company passed the continuous certification of high-tech enterprises.

In 2004, the national Class IV new drugs "Donepezil Hydrochloride" (raw material, preparation) and "Formotero fumarate" (raw material, preparation) obtained new drug certificates and production approval numbers.